Gland Pharma to acquire 100 percent stake in Cenexi Group
New Delhi: Drug firm Gland Pharma has inked a pact with FPCI Sino French Midcap Fund to acquire 100 percent stake in Europe-based Cenexi Group.
Gland Pharma International PTE, a Singapore-based wholly owned subsidiary of the company, has entered into a share purchase agreement with FPCI Sino French Midcap Fund to fully acquire stake in Cenexi pursuant to the terms of the put option agreement inked in November last year.
On November 29, 2022, the Hyderabad-based drug contract development and manufacturing company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to EUR 120 million (around Rs 1,015 crore), marking its foray into the international markets.
Under the put option, an entity gets the right not obligation to sell a specified amount or stake at a predetermined price.
Read also: Gland Pharma Singapore arm to acquire Cenexi Group for over Rs 1000 crore
Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill-finished drugs, including capabilities on oncology and complex products.
It has a presence across four manufacturing sites in Europe which include three sites in France and one site in Belgium.
The company, which employs 1,372 people, has experience in processing specific substances like hormones, suspensions and controlled substances.
Its revenue for the 2021 calendar year stood at EUR 184.1 million.
Read also: Gland Pharma bags USFDA nod for Cangrelor for Injection
Gland Pharma, a generic injectable-focused pharmaceutical company, was established in 1978 in Hyderabad. The company is present in sterile injectables, oncology, and ophthalmic segments and focuses on complex injectables, including NCE-1s, First-to-File products, and 505(b)(2) filings. Its products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops.
Read also: Gland Pharma gets tentative USFDA nod for generic version of Bridion injection
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.